CN108498782A - A kind of composition and preparation method thereof for treating cardiovascular and cerebrovascular disease - Google Patents
A kind of composition and preparation method thereof for treating cardiovascular and cerebrovascular disease Download PDFInfo
- Publication number
- CN108498782A CN108498782A CN201810590070.5A CN201810590070A CN108498782A CN 108498782 A CN108498782 A CN 108498782A CN 201810590070 A CN201810590070 A CN 201810590070A CN 108498782 A CN108498782 A CN 108498782A
- Authority
- CN
- China
- Prior art keywords
- parts
- extract
- composition
- cardiovascular
- cerebrovascular disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 70
- 230000002526 effect on cardiovascular system Effects 0.000 title claims abstract description 42
- 208000026106 cerebrovascular disease Diseases 0.000 title claims abstract description 41
- 208000024172 Cardiovascular disease Diseases 0.000 title claims abstract description 38
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 239000000284 extract Substances 0.000 claims abstract description 136
- 239000000843 powder Substances 0.000 claims abstract description 50
- 241000382353 Pupa Species 0.000 claims abstract description 43
- 235000003130 Arctium lappa Nutrition 0.000 claims abstract description 41
- 235000008078 Arctium minus Nutrition 0.000 claims abstract description 41
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 41
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 41
- 235000013557 nattō Nutrition 0.000 claims abstract description 35
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 34
- 235000003145 Hippophae rhamnoides Nutrition 0.000 claims abstract description 33
- 229920001184 polypeptide Polymers 0.000 claims abstract description 33
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 33
- 235000017276 Salvia Nutrition 0.000 claims abstract description 32
- 239000002994 raw material Substances 0.000 claims abstract description 27
- 240000000950 Hippophae rhamnoides Species 0.000 claims abstract description 21
- 229940087603 grape seed extract Drugs 0.000 claims abstract description 21
- 235000002532 grape seed extract Nutrition 0.000 claims abstract description 21
- 239000001717 vitis vinifera seed extract Substances 0.000 claims abstract description 21
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 claims abstract description 18
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims abstract description 18
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims abstract description 18
- 239000003814 drug Substances 0.000 claims abstract description 8
- 229940079593 drug Drugs 0.000 claims abstract description 5
- 241000208843 Arctium Species 0.000 claims description 40
- 241000933832 Broussonetia Species 0.000 claims description 34
- 241001072909 Salvia Species 0.000 claims description 31
- 239000002245 particle Substances 0.000 claims description 20
- 235000009754 Vitis X bourquina Nutrition 0.000 claims description 15
- 235000012333 Vitis X labruscana Nutrition 0.000 claims description 15
- 235000014787 Vitis vinifera Nutrition 0.000 claims description 15
- 238000000605 extraction Methods 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 9
- 241000180649 Panax notoginseng Species 0.000 claims description 9
- 238000005238 degreasing Methods 0.000 claims description 9
- 238000001035 drying Methods 0.000 claims description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 240000000249 Morus alba Species 0.000 claims description 6
- 235000008708 Morus alba Nutrition 0.000 claims description 6
- 210000004556 brain Anatomy 0.000 claims description 6
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 238000000227 grinding Methods 0.000 claims description 6
- WTPPRJKFRFIQKT-UHFFFAOYSA-N 1,6-dimethyl-8,9-dihydronaphtho[1,2-g][1]benzofuran-10,11-dione;1-methyl-6-methylidene-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-10,11-dione Chemical compound O=C1C(=O)C2=C3CCCC(=C)C3=CC=C2C2=C1C(C)=CO2.O=C1C(=O)C2=C3CCC=C(C)C3=CC=C2C2=C1C(C)=CO2 WTPPRJKFRFIQKT-UHFFFAOYSA-N 0.000 claims description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 5
- 235000010204 pine bark Nutrition 0.000 claims description 5
- 244000132619 red sage Species 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 4
- 238000002137 ultrasound extraction Methods 0.000 claims description 4
- 238000001291 vacuum drying Methods 0.000 claims description 4
- 241000235342 Saccharomycetes Species 0.000 claims description 3
- 244000061456 Solanum tuberosum Species 0.000 claims description 3
- 235000002595 Solanum tuberosum Nutrition 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 claims description 3
- 210000002216 heart Anatomy 0.000 claims description 3
- 239000012535 impurity Substances 0.000 claims description 3
- 238000010792 warming Methods 0.000 claims description 3
- 108091005804 Peptidases Proteins 0.000 claims description 2
- 239000004365 Protease Substances 0.000 claims description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 2
- 239000001569 carbon dioxide Substances 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 235000013402 health food Nutrition 0.000 claims description 2
- 239000003208 petroleum Substances 0.000 claims description 2
- 238000000194 supercritical-fluid extraction Methods 0.000 claims description 2
- 238000002604 ultrasonography Methods 0.000 claims description 2
- 240000006365 Vitis vinifera Species 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 19
- 230000001225 therapeutic effect Effects 0.000 abstract description 13
- 206010008118 cerebral infarction Diseases 0.000 abstract description 12
- 201000006474 Brain Ischemia Diseases 0.000 abstract description 9
- 206010008120 Cerebral ischaemia Diseases 0.000 abstract description 9
- 208000031225 myocardial ischemia Diseases 0.000 abstract description 8
- 238000002474 experimental method Methods 0.000 abstract description 6
- 230000002195 synergetic effect Effects 0.000 abstract description 4
- 239000002131 composite material Substances 0.000 abstract description 2
- 238000011835 investigation Methods 0.000 abstract description 2
- 230000010534 mechanism of action Effects 0.000 abstract description 2
- 240000005528 Arctium lappa Species 0.000 abstract 1
- 240000006248 Broussonetia kazinoki Species 0.000 abstract 1
- 240000007164 Salvia officinalis Species 0.000 abstract 1
- 230000000052 comparative effect Effects 0.000 description 16
- 241000219095 Vitis Species 0.000 description 13
- 241000229143 Hippophae Species 0.000 description 12
- 241000700159 Rattus Species 0.000 description 8
- 238000000855 fermentation Methods 0.000 description 5
- 230000004151 fermentation Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 208000010125 myocardial infarction Diseases 0.000 description 4
- 241000209140 Triticum Species 0.000 description 3
- 235000021307 Triticum Nutrition 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 210000000269 carotid artery external Anatomy 0.000 description 3
- 235000013339 cereals Nutrition 0.000 description 3
- 210000000038 chest Anatomy 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 2
- 235000011613 Pinus brutia Nutrition 0.000 description 2
- 241000018646 Pinus brutia Species 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000004576 sand Substances 0.000 description 2
- 208000019553 vascular disease Diseases 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 101800004637 Communis Proteins 0.000 description 1
- 206010011086 Coronary artery occlusion Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
- A61K36/15—Pinaceae (Pine family), e.g. pine or cedar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Polymers & Plastics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a kind of compositions and preparation method thereof for treating cardiovascular and cerebrovascular disease.The composition of the treatment cardiovascular and cerebrovascular disease is made from the following raw materials in parts by weight：10~20 parts of grape seed extract, 5~20 parts of natto extract, 5~10 parts of Notogineng Extract, 5~10 parts of Salvia root P.E, 5~10 parts of burdock extract, 5~10 parts of hippophae rhamnoides, 5~10 parts of kudzu root extract, 5~10 parts of Pine Bark, 1~5 part of bee pupa polypeptide, 5~15 parts of Folium Mori fermented product, 5~15 parts of feed with paper-mulberry leaf fermentate, 1~5 part of arabinose powder.Further investigation according to the present invention experiment, composition of the invention have significant resist myocardial ischemia and treating cerebral ischemia, each component of composition of the invention have good synergistic effect, can play the therapeutic effect of globality.In addition, the composition material source of the present invention is easy to get, stable and controllable for quality, drug ingedient and the mechanism of action are clear, can take for a long time, without side-effects, safety, good absorbing.
Description
Technical field
The present invention relates to technical field of traditional Chinese medicines, more particularly to a kind of composition for treating cardiovascular and cerebrovascular disease and its preparation side
Method.
Background technology
Cardiovascular and cerebrovascular disease is the general designation of cardiovascular and cranial vascular disease, refers to due to hyperlipidemia, blood viscousness, moves
The ischemic or hemorrhagic disease that heart, brain and body tissue caused by pulse atherosclerosis, hypertension etc. occur, are such as preced with
Worry, myocardial infarction, the rhomboembolia type cerebrovascular are the big persistent ailments for threatening World Health crowd, old in especially 50 years old or more
The common disease of year people's health, has the characteristics that high illness rate, high disability rate and high mortality, and what is gradually risen in recent years becomes
Gesture.The height of mortality of cardio and cerebral vascular disease is the quality of life for weighing a country resident, sanitary health career
Important indicator.Even if application treatment means most advanced, most perfect at present, still can have 50% or more cardiovascular and cerebrovascular surprisingly to survive
Person's life cannot take care of oneself completely, and the number that cardiovascular and cerebrovascular disease is died of in the whole world every year is up to 15,000,000 people, and it is first to occupy the various causes of the death
Position.
The related drugs of the treatment cardiovascular and cerebrovascular disease occurred currently on the market, it is typically mixed by simple traditional Chinese medicine ingredients
Conjunction is made, although there is certain effect, availability is not high, not easy for human absorption, slowly effect, and secondary make easily occurs
With, certain burden is caused to the stomach of person in middle and old age, it is unsuitable to take for a long time.
Invention content
The purpose of the present invention is intended to provide a kind of composition and preparation method thereof for treating cardiovascular and cerebrovascular disease, in solution
State technical problem.
To achieve the goals above, the technical scheme is that：
In a first aspect, a kind of composition for treating cardiovascular and cerebrovascular disease provided by the invention, by the raw material of following parts by weight
It is made：10~20 parts of grape seed extract, 5~20 parts of natto extract, 5~10 parts of Notogineng Extract, Salvia root P.E 5~10
Part, 5~10 parts of burdock extract, 5~10 parts of hippophae rhamnoides, 5~10 parts of kudzu root extract, 5~10 parts of Pine Bark,
1~5 part of bee pupa polypeptide, 5~15 parts of Folium Mori fermented product, 5~15 parts of feed with paper-mulberry leaf fermentate, 1~5 part of arabinose powder.
Preferably, the composition of the treatment cardiovascular and cerebrovascular disease is made from the following raw materials in parts by weight：Grape pip extracts
12~17 parts of object, 7~14 parts of natto extract, 5~8 parts of Notogineng Extract, 6~9 parts of Salvia root P.E, burdock extract 5~7
Part, 5~8 parts of hippophae rhamnoides, 5~8 parts of kudzu root extract, 5~8 parts of Pine Bark, 3~4 parts of bee pupa polypeptide, mulberry leaf hair
12~15 parts of ferment object, 8~10 parts of feed with paper-mulberry leaf fermentate, 1~3 part of arabinose powder.
Preferably, the grape seed extract, natto extract, hippophae rhamnoides are to be extracted using CO 2 supercritical
It follows the example of obtained.
Preferably, the Notogineng Extract, Salvia root P.E, burdock extract, kudzu root extract are using following sides
Method is made：
It will be cleaned after Radix Notoginseng, Radix Salviae Miltiorrhizae, burdock, pueraria lobata removal impurity respectively, after 20~30 DEG C of vacuum drying, be ground into grain size
For the particle of 2.5~3.2mm, Radix Notoginseng particle, DANSHEN KELI, burdock particle, pueraria lobata particle are respectively obtained, by the Radix Notoginseng of gained
Grain, DANSHEN KELI, burdock particle and pueraria lobata particle immerse in ethanol solution respectively, 1~3h of ultrasonic extraction, after extraction, warp
Filtering, concentration, dry, crushing obtain Notogineng Extract, Salvia root P.E, burdock extract, kudzu root extract.
Preferably, the Folium Mori fermented product, feed with paper-mulberry leaf fermentate are to be made using following methods：
After mulberry leaf, feed with paper-mulberry leaf are crushed respectively, be added 0.8~1.2 times of its quality dehydrated potato powder and 0.3~0.7 times
Water accesses the saccharomycete of its quality 2% after mixing, is placed in 28~30 DEG C of Anaerobic culturels 3~5 days, through 20~30 DEG C of vacuum
After drying, ultramicro grinding is carried out, Folium Mori fermented product, feed with paper-mulberry leaf fermentate are obtained.
Preferably, the Pine Bark is to be made using following methods：
Pine bark is crushed to 200~800 mesh powders, under the conditions of 4~25 DEG C, the powder of gained is soaked into water
In, Pine Bark is made through filtering, concentration, drying, ultramicro grinding, wherein the water is pine tree in 1~3h of ultrasonic extraction
10~15 times of the weight of skin powder.
Preferably, the bee pupa polypeptide is to be made using following methods：
Bee pupa is crushed to 100~300 mesh powders, under conditions of 20~40 DEG C, oil is added in the powder of gained
Degreasing in ether air-dries and obtains the bee pupa powder of degreasing；By the bee pupa powder and albumen of the degreasing of gained under the conditions of 40~50 DEG C
3~4h is hydrolyzed after enzyme mixing, then is warming up to 10~20min of standing at 95~100 DEG C, is centrifuged, is concentrated in vacuo and freezes
It is dried to obtain bee pupa polypeptide.
Second aspect, a kind of composition of the treatment cardiovascular and cerebrovascular disease prepared as described in relation to the first aspect provided by the invention
Preparation method, include the following steps：
By formula ratio, by grape seed extract, natto extract, Notogineng Extract, Salvia root P.E, burdock extract,
Hippophae rhamnoides, kudzu root extract, Pine Bark, bee pupa polypeptide, Folium Mori fermented product, feed with paper-mulberry leaf fermentate and arabinose
Powder is uniformly mixed the composition that treatment cardiovascular and cerebrovascular disease is made.
The composition of the third aspect, a kind for the treatment of cardiovascular and cerebrovascular disease as described in relation to the first aspect provided by the invention is being made
Application in standby health food.
The composition of fourth aspect, a kind for the treatment of cardiovascular and cerebrovascular disease as described in relation to the first aspect provided by the invention is being made
Application in the drug of standby treatment cardiovascular and cerebrovascular.
Compared with prior art, the beneficial effects of the present invention are：
Further investigation according to the present invention experiment, composition of the invention have significant resist myocardial ischemia and anti-cerebral ischemia
The each component of effect, composition of the invention has good synergistic effect, can play the therapeutic effect of globality.In addition, this
The composition material source of invention is easy to get, stable and controllable for quality, and drug ingedient and the mechanism of action are clear, can take for a long time, no pair
Effect, safety, good absorbing.
Description of the drawings
Fig. 1 is the block diagram of the therapeutic effect of cerebral ischemia；
Fig. 2 is the block diagram of the therapeutic effect of myocardial ischemia.
Specific implementation mode
To make the object, technical solutions and advantages of the present invention clearer, below in conjunction with attached drawing to the technology of the present invention
Scheme is described in detail.Obviously, described embodiments are only a part of the embodiments of the present invention, rather than whole realities
Apply example.Based on the embodiments of the present invention, those of ordinary skill in the art without making creative work gained
The all other embodiment arrived belongs to the range that the present invention is protected.
Embodiment 1
A kind of preparation method of composition for treating cardiovascular and cerebrovascular disease provided in this embodiment, includes the following steps：
(1) preparation of grape seed extract, natto extract, hippophae rhamnoides：
It is to be made using carbon dioxide supercritical extraction method, specifically, clean grape pip, natto, sea-buckthorn are drenched dry
After moisture, it is dried to moisture and is less than 5%, the grape pip after drying is crushed by disintegrating apparatus, the grape of 30 mesh is made
Powder of seeds, natto powder and Seabuckthorn Fruit, it is spare；Grape pip powder, natto powder and Seabuckthorn Fruit are respectively charged into 3 and extracted
It takes in kettle, by the CO of supercriticality2It is injected separately into above-mentioned 3 extraction kettles, wherein the extraction conditions of grape pip powder is：
Temperature 50 C, extracting pressure 28Mpa, CO2Flow velocity 0.1L/min, extraction time 2.5h, the extraction conditions of natto powder are：Temperature
40 DEG C, extracting pressure 25Mpa, CO2Flow velocity 0.12L/min, extraction time 2h, the extraction conditions of Seabuckthorn Fruit are：Temperature is 50
DEG C, pressure 1.5Mpa, CO2Flow velocity 0.15L/min, extraction time 4h；Respectively by grape seed extract, natto extract, sand
The CO of spine extract2Fluid separates grape seed extract, natto extract, hippophae rhamnoides into 3 separating stills, CO2
Gas enters extraction kettle and recycles after compression.
(2) preparation of Notogineng Extract, Salvia root P.E, burdock extract, kudzu root extract：
It will be cleaned after Radix Notoginseng, Radix Salviae Miltiorrhizae, burdock, pueraria lobata removal impurity respectively, after 240 DEG C of vacuum drying, being ground into grain size is
The particle of 3.0mm respectively obtains Radix Notoginseng particle, DANSHEN KELI, burdock particle, pueraria lobata particle, by Radix Notoginseng particle, the Radix Salviae Miltiorrhizae of gained
Particle, burdock particle and pueraria lobata particle are immersed in respectively in the ethanol solution of 10 times of its weight, and ultrasonic extraction 2.5h, extraction finishes
Afterwards, Notogineng Extract, Salvia root P.E, burdock extract, kudzu root extract are obtained through filtering, concentration, drying, crushing.
(3) preparation of Folium Mori fermented product, feed with paper-mulberry leaf fermentate：
After respectively crushing mulberry leaf, feed with paper-mulberry leaf, its dehydrated potato powder identical in quality and 0.5 times of water is added, is uniformly mixed
Afterwards, the saccharomycete for accessing its quality 2%, is placed in 28 DEG C of Anaerobic culturels 4 days, after 24 DEG C of vacuum drying, carries out ultramicro grinding, obtains
To Folium Mori fermented product, feed with paper-mulberry leaf fermentate.
(4) preparation of Pine Bark：
Pine bark is crushed to 300 mesh powders, under the conditions of 16 DEG C, the powder of gained is soaked into water, ultrasound carries
2.5h is taken, Pine Bark is made through filtering, concentration, drying, ultramicro grinding, wherein the water is the weight of pine bark powder
12 times.
(5) preparation of bee pupa polypeptide：
Bee pupa is crushed to 200 mesh powders, under conditions of 30 DEG C, by the powder of gained be added degreasing in petroleum ether,
It air-dries and obtains the bee pupa powder of degreasing；It is hydrolyzed after mixing the bee pupa powder of the degreasing of gained with protease under the conditions of 45 DEG C
3.5h, then be warming up at 90 DEG C and stand 15min is centrifuged, is concentrated in vacuo and freeze-drying obtains bee pupa polypeptide.
(6) preparation of wheat germ powder：For by wheat embryo low temperature drying, simultaneously liquid nitrogen grinding obtains, the wheat germ powder
Size be 100 mesh；
(7) raw material obtained by above-mentioned steps is weighed according to parts by weight：10 parts of grape seed extract, natto extract 20
Part, 5 parts of Notogineng Extract, 5 parts of Salvia root P.E, 5 parts of burdock extract, 5 parts of hippophae rhamnoides, 10 parts of kudzu root extract, pine
10 parts of bark extract, 5 parts of bee pupa polypeptide, 15 parts of Folium Mori fermented product, 5 parts of feed with paper-mulberry leaf fermentate, 5 parts of arabinose powder；It will claim
The raw material taken is uniformly mixed the composition that treatment cardiovascular and cerebrovascular disease is made.
Embodiment 2
The step of advantageous effect in order to further illustrate the present invention, the repetition embodiment of the present invention 1 (1) to step (6), system
Grape seed extract, natto extract, Notogineng Extract, Salvia root P.E, burdock extract, hippophae rhamnoides, pueraria lobata is obtained to carry
Take object, Pine Bark, bee pupa polypeptide, Folium Mori fermented product, feed with paper-mulberry leaf fermentate；Raw material is weighed according to parts by weight：Grape
20 parts of seed extract, 10 parts of natto extract, 10 parts of Notogineng Extract, 10 parts of Salvia root P.E, 10 parts of burdock extract, sea-buckthorn
10 parts of extract, 5 parts of kudzu root extract, 5 parts of Pine Bark, 1 part of bee pupa polypeptide, 5 parts of Folium Mori fermented product, feed with paper-mulberry leaf fermentation
15 parts of object, 1 part of arabinose powder；The raw material weighed is uniformly mixed to the composition that treatment cardiovascular and cerebrovascular disease is made.
Embodiment 3
The step of advantageous effect in order to further illustrate the present invention, the repetition embodiment of the present invention 1 (1) to step (6), system
Grape seed extract, natto extract, Notogineng Extract, Salvia root P.E, burdock extract, hippophae rhamnoides, pueraria lobata is obtained to carry
Take object, Pine Bark, bee pupa polypeptide, Folium Mori fermented product, feed with paper-mulberry leaf fermentate；Raw material is weighed according to parts by weight：Grape
18 parts of seed extract, 16 parts of natto extract, 5 parts of Notogineng Extract, 8 parts of Salvia root P.E, 8 parts of burdock extract, sea-buckthorn carry
Take 10 parts of object, 9 parts of kudzu root extract, 10 parts of Pine Bark, 2 parts of bee pupa polypeptide, 10 parts of Folium Mori fermented product, feed with paper-mulberry leaf fermentation
12 parts of object, 4 parts of arabinose powder；The raw material weighed is uniformly mixed to the composition that treatment cardiovascular and cerebrovascular disease is made.
Embodiment 4
The step of advantageous effect in order to further illustrate the present invention, the repetition embodiment of the present invention 1 (1) to step (6), system
Grape seed extract, natto extract, Notogineng Extract, Salvia root P.E, burdock extract, hippophae rhamnoides, pueraria lobata is obtained to carry
Take object, Pine Bark, bee pupa polypeptide, Folium Mori fermented product, feed with paper-mulberry leaf fermentate；Raw material is weighed according to parts by weight：Grape
11 parts of seed extract, 18 parts of natto extract, 9 parts of Notogineng Extract, 5 parts of Salvia root P.E, 9 parts of burdock extract, sea-buckthorn carry
Take 9 parts of object, 9 parts of kudzu root extract, 9 parts of Pine Bark, 4.5 parts of bee pupa polypeptide, 8 parts of Folium Mori fermented product, feed with paper-mulberry leaf fermentation
7.5 parts of object, 3.5 parts of arabinose powder；The raw material weighed is uniformly mixed to the composition that treatment cardiovascular and cerebrovascular disease is made.
Embodiment 5
The step of advantageous effect in order to further illustrate the present invention, the repetition embodiment of the present invention 1 (1) to step (6), system
Grape seed extract, natto extract, Notogineng Extract, Salvia root P.E, burdock extract, hippophae rhamnoides, pueraria lobata is obtained to carry
Take object, Pine Bark, bee pupa polypeptide, Folium Mori fermented product, feed with paper-mulberry leaf fermentate；Raw material is weighed according to parts by weight：Grape
12 parts of seed extract, 14 parts of natto extract, 8 parts of Notogineng Extract, 6 parts of Salvia root P.E, 5 parts of burdock extract, sea-buckthorn carry
Take 5 parts of object, 5 parts of kudzu root extract, 5 parts of Pine Bark, 3 parts of bee pupa polypeptide, 15 parts of Folium Mori fermented product, feed with paper-mulberry leaf fermentate
8 parts, 1 part of arabinose powder；The raw material weighed is uniformly mixed to the composition that treatment cardiovascular and cerebrovascular disease is made.
Embodiment 6
The step of advantageous effect in order to further illustrate the present invention, the repetition embodiment of the present invention 1 (1) to step (6), system
Grape seed extract, natto extract, Notogineng Extract, Salvia root P.E, burdock extract, hippophae rhamnoides, pueraria lobata is obtained to carry
Take object, Pine Bark, bee pupa polypeptide, Folium Mori fermented product, feed with paper-mulberry leaf fermentate；Raw material is weighed according to parts by weight：Grape
15 parts of seed extract, 12 parts of natto extract, 6 parts of Notogineng Extract, 7.5 parts of Salvia root P.E, 6 parts of burdock extract, sea-buckthorn
6 parts of extract, 7 parts of kudzu root extract, 7 parts of Pine Bark, 3.5 parts of bee pupa polypeptide, 14 parts of Folium Mori fermented product, feed with paper-mulberry leaf hair
9 parts of ferment object, 2.5 parts of arabinose powder；The raw material weighed is uniformly mixed to the composition that treatment cardiovascular and cerebrovascular disease is made.
Embodiment 7
The step of advantageous effect in order to further illustrate the present invention, the repetition embodiment of the present invention 1 (1) to step (6), system
Grape seed extract, natto extract, Notogineng Extract, Salvia root P.E, burdock extract, hippophae rhamnoides, pueraria lobata is obtained to carry
Take object, Pine Bark, bee pupa polypeptide, Folium Mori fermented product, feed with paper-mulberry leaf fermentate；Raw material is weighed according to parts by weight：Grape
17 parts of seed extract, 7 parts of natto extract, 5 parts of Notogineng Extract, 9 parts of Salvia root P.E, 7 parts of burdock extract, sea-buckthorn extraction
8 parts of object, 8 parts of kudzu root extract, 8 parts of Pine Bark, 4 parts of bee pupa polypeptide, 12 parts of Folium Mori fermented product, feed with paper-mulberry leaf fermentate 10
Part, 3 parts of arabinose powder；The raw material weighed is uniformly mixed to the composition that treatment cardiovascular and cerebrovascular disease is made.
Comparative example 1
The step of advantageous effect in order to further illustrate the present invention, the repetition embodiment of the present invention 1 (2) to step (6), system
Obtain Notogineng Extract, Salvia root P.E, burdock extract, kudzu root extract, Pine Bark, bee pupa polypeptide, mulberry leaf fermentation
Object, feed with paper-mulberry leaf fermentate；Raw material is weighed according to parts by weight：5 parts of Notogineng Extract, 5 parts of Salvia root P.E, burdock extract 5
Part, 10 parts of kudzu root extract, 10 parts of Pine Bark, 5 parts of bee pupa polypeptide, 15 parts of Folium Mori fermented product, feed with paper-mulberry leaf fermentate 5
Part, 5 parts of arabinose powder；The raw material weighed is uniformly mixed to the composition that treatment cardiovascular and cerebrovascular disease is made.
Comparative example 2
The step of advantageous effect in order to further illustrate the present invention, the repetition embodiment of the present invention 1 (1), step (2), step
Suddenly (4) to step (6), be made grape seed extract, natto extract, Notogineng Extract, Salvia root P.E, burdock extract,
Hippophae rhamnoides, kudzu root extract, Pine Bark, bee pupa polypeptide,；Raw material is weighed according to parts by weight：Grape pip extracts
10 parts of object, 20 parts of natto extract, 5 parts of Notogineng Extract, 5 parts of Salvia root P.E, 5 parts of burdock extract, hippophae rhamnoides 5
Part, 10 parts of kudzu root extract, 10 parts of Pine Bark, 5 parts of bee pupa polypeptide, 5 parts of arabinose powder；The raw material weighed is mixed
The composition for the treatment of cardiovascular and cerebrovascular disease is uniformly made.
Comparative example 3
The step of advantageous effect in order to further illustrate the present invention, the repetition embodiment of the present invention 1 (1), step (3) to step
Suddenly grape seed extract, natto extract, hippophae rhamnoides, Pine Bark, bee pupa polypeptide, mulberry leaf fermentation is made in (6)
Object, feed with paper-mulberry leaf fermentate；Raw material is weighed according to parts by weight：10 parts of grape seed extract, 20 parts of natto extract, sea-buckthorn extraction
5 parts of object, 10 parts of Pine Bark, 5 parts of bee pupa polypeptide, 15 parts of Folium Mori fermented product, 5 parts of feed with paper-mulberry leaf fermentate, arabinose powder 5
Part；The raw material weighed is uniformly mixed to the composition that treatment cardiovascular and cerebrovascular disease is made.
Comparative example 4
Advantageous effect in order to further illustrate the present invention, repeat the embodiment of the present invention 1 the step of (1) to step (3), step
Suddenly grape seed extract, natto extract, Notogineng Extract, Salvia root P.E, burdock extract, sand is made in (5), step (6)
Spine extract, kudzu root extract, bee pupa polypeptide, Folium Mori fermented product, feed with paper-mulberry leaf fermentate；Raw material is weighed according to parts by weight：Portugal
10 parts of grape seed extract, 20 parts of natto extract, 5 parts of Notogineng Extract, 5 parts of Salvia root P.E, 5 parts of burdock extract, sea-buckthorn
5 parts of extract, 10 parts of kudzu root extract, 5 parts of bee pupa polypeptide, 15 parts of Folium Mori fermented product, 5 parts of feed with paper-mulberry leaf fermentate, arabinose
5 parts of powder；The raw material weighed is uniformly mixed to the composition that treatment cardiovascular and cerebrovascular disease is made.
The therapeutic effect of 1 cerebral ischemia of effect example is tested
(1) sample：By the composition obtained by Examples 1 to 7 and comparative example 1~4.
(2) experimental animal：Healthy SD Kunming rat, male, weight are 180~220g, are tested by Kunming Medical University dynamic
Object center provides.
(3) the therapeutic effect experiment of cerebral ischemia：Rat 240 is taken, is randomly divided into 24 groups, every group 10, modeling the last week,
Each medicine group gastric infusion 50mg/Kg, model group gavage give the distilled water of equivalent, once a day, continuous 7 days, specific to be grouped
With administration referring to table 1.
The therapeutic effect experiment grouping of 1 cerebral ischemia of table
| Group | Sample | Dosage | Size of animal |
| 1 | The composition of embodiment 1 | 50mg/Kg | 10 |
| 2 | The composition of embodiment 2 | 50mg/Kg | 10 |
| 3 | The composition of embodiment 3 | 50mg/Kg | 10 |
| 4 | The composition of embodiment 4 | 50mg/Kg | 10 |
| 5 | The composition of embodiment 5 | 50mg/Kg | 10 |
| 6 | The composition of embodiment 6 | 50mg/Kg | 10 |
| 7 | The composition of embodiment 7 | 50mg/Kg | 10 |
| 8 | The composition of comparative example 1 | 50mg/Kg | 10 |
| 9 | The composition of comparative example 2 | 50mg/Kg | 10 |
| 10 | The composition of comparative example 3 | 50mg/Kg | 10 |
| 11 | The composition of comparative example 4 | 50mg/Kg | 10 |
| Model group | —— | 50mg/Kg | 10 |
After last dose 2 hours, each group rat is taken, with 3.5% chloraldurate 15ml/Kg intraperitoneal injection of anesthesia, it is solid to face upward position
It is fixed, an about 3cm long mouths are cut off from neck center is longitudinal with operating scissors, sharp blunt combination detaches cervical fascia, and right side is isolated with tweezers
Arteria carotis communis wears two surgical threads around right carotid, in case ligation, is isolated along right carotid to cephalad direction
External carotid artery and internal carotid wear a surgical thread around external carotid artery, are ligatured respectively with filament dynamic outside right carotid and neck
Arteries and veins opens an osculum with eye scissors in right carotid proximal part, and opening is about from external carotid artery and internal carotid crotch
0.5cm is inserted into fishing line from incision, and insertion depth about 18mm stops inlet wire when feeling to have resistance sense at this time, block in brain and move
Arteries and veins leads to cerebral ischemia, ligatures fixed fishing line, disinfection, layer-by-layer suture muscle and skin.After modeling 24 hours, breaks end and take brain, -80 DEG C
10min is freezed, the coronal brain piece for being averagely cut into thickness about 2mm is put into rapidly in 4%TTC dye liquors, and 37 DEG C are protected from light incubation 30min, every
15min is stirred once, is taken out after stirring second, is set in 4% paraformaldehyde liquid and be kept in dark place 24 hours.Non- ischemic after dyed
Area is rose, and infarct is white.White area carefully is dug down, is weighed, cerebral infarction percentage is calculated.Cerebral infarction percentage
(%)=Cerebral Infarction weight/brain gross weight × 100%, experimental result is referring to Fig. 1.
Fig. 2's the result shows that, good to the therapeutic effect of cerebral ischemia according to composition made from Examples 1 to 7, curative effect is excellent
According to the composition obtained by comparative example 1~4, show that each component of the composition of the present invention has good synergistic effect,
The therapeutic effect of globality can be played.
The therapeutic effect of 2 myocardial ischemia of effect example is tested
(1) sample：By the composition obtained by Examples 1 to 7 and comparative example 1~4.
(2) experimental animal：Healthy SD Kunming rat, male, weight are 180~220g, are tested by Kunming Medical University dynamic
Object center provides.
(3) the therapeutic effect experiment of cerebral ischemia：Rat 240 is taken, is randomly divided into 24 groups, every group 10, modeling the last week,
Each medicine group gastric infusion 50mg/Kg, model group gavage give the distilled water of equivalent, once a day, continuous 7 days, specific to be grouped
With administration referring to table 2.
The therapeutic effect experiment grouping of 2 myocardial ischemia of table
| Group | Sample | Dosage | Size of animal |
| 1 | The composition of embodiment 1 | 50mg/Kg | 10 |
| 2 | The composition of embodiment 2 | 50mg/Kg | 10 |
| 3 | The composition of embodiment 3 | 50mg/Kg | 10 |
| 4 | The composition of embodiment 4 | 50mg/Kg | 10 |
| 5 | The composition of embodiment 5 | 50mg/Kg | 10 |
| 6 | The composition of embodiment 6 | 50mg/Kg | 10 |
| 7 | The composition of embodiment 7 | 50mg/Kg | 10 |
| 8 | The composition of comparative example 1 | 50mg/Kg | 10 |
| 9 | The composition of comparative example 2 | 50mg/Kg | 10 |
| 10 | The composition of comparative example 3 | 50mg/Kg | 10 |
| 11 | The composition of comparative example 4 | 50mg/Kg | 10 |
| Model group | —— | 50mg/Kg | 10 |
After last dose 2 hours, each group rat is taken, with 10% urethane 1ml/Kg intraperitoneal injection of anesthesia, position is faced upward and fixes
Rat, the detection of standard II lead electrocardiogram, connection trachea cannula couple breathing apparatus after opening chest；The mouse hair of chest is cut off,
The 3rd~5 rib cage of longitudinal incision at 0.5cm by the left border of sternum, cuts off pericardium, exposure heart, following coronary artery occlusion descending anterior branch,
A diameter 2mm plastic tube is placed between ligature and coronary artery simultaneously, tensing ligature makes plastic tube compressing cause to be preced with
Arteries and veins occludes, and causes acute myocardial ischemia, increases (＞ 0.2mV) when there are T-ST amplitudes, i.e. myocardial ischemia in rats model success.It lacks
After blood 30min, plastic tube is pumped, carries out Reperfu- sion 60min；After ligaturing coronary artery for 24 hours, coring is dirty, -80 DEG C of frost 5min,
Coronary sulcus is parallel under ligature by crosscutting 5 of left ventricle, in 37 DEG C of dyeing 6min of 1%TTC solution, suck dry moisture after dyeing,
Measure myocardial infarction area area, calculating myocardium infarct percentage.Myocardial infarction percentage (%)=myocardial infarction area area/ventricle
Area × 100%, experimental result is referring to Fig. 2.
Fig. 2's the result shows that, by composition made from Examples 1 to 7 have significant function of resisting myocardial ischemia, curative effect
Better than by the made composition of comparative example 1~4, show that each component of the composition of the present invention has good synergistic effect, energy
Play the therapeutic effect of globality.
The above description is merely a specific embodiment, but scope of protection of the present invention is not limited thereto, any
Those familiar with the art in the technical scope disclosed by the present invention, can easily think of the change or the replacement, and should all contain
Lid is within protection scope of the present invention.Therefore, protection scope of the present invention should be based on the protection scope of the described claims.
Claims (10)
1. a kind of composition for treating cardiovascular and cerebrovascular disease, it is characterised in that：It is made from the following raw materials in parts by weight：Grape pip carries
Take 10~20 parts of object, 5~20 parts of natto extract, 5~10 parts of Notogineng Extract, 5~10 parts of Salvia root P.E, burdock extract
5~10 parts, 5~10 parts of hippophae rhamnoides, 5~10 parts of kudzu root extract, 5~10 parts of Pine Bark, bee pupa polypeptide 1~5
Part, 5~15 parts of Folium Mori fermented product, 5~15 parts of feed with paper-mulberry leaf fermentate, 1~5 part of arabinose powder.
2. the composition for the treatment of cardiovascular and cerebrovascular disease according to claim 1, it is characterised in that：The treatment cardiovascular and cerebrovascular
The composition of disease is made from the following raw materials in parts by weight：12~17 parts of grape seed extract, 7~14 parts of natto extract, three
Seven 5~8 parts of extracts, 6~9 parts of Salvia root P.E, 5~7 parts of burdock extract, 5~8 parts of hippophae rhamnoides, kudzu root extract 5
~8 parts, 5~8 parts of Pine Bark, 3~4 parts of bee pupa polypeptide, 12~15 parts of Folium Mori fermented product, feed with paper-mulberry leaf fermentate 8~10
Part, 1~3 part of arabinose powder.
3. the composition for the treatment of cardiovascular and cerebrovascular disease according to claim 1, it is characterised in that：The grape pip extraction
Object, natto extract, hippophae rhamnoides are to be made using carbon dioxide supercritical extraction method.
4. the composition for the treatment of cardiovascular and cerebrovascular disease according to claim 1, it is characterised in that：The Notogineng Extract,
Salvia root P.E, burdock extract, kudzu root extract are to be made using following methods：
It will be cleaned after Radix Notoginseng, Radix Salviae Miltiorrhizae, burdock, pueraria lobata removal impurity respectively, after 20~30 DEG C of vacuum drying, being ground into grain size is
The particle of 2.5~3.2mm respectively obtains Radix Notoginseng particle, DANSHEN KELI, burdock particle, pueraria lobata particle, by the Radix Notoginseng of gained
Grain, DANSHEN KELI, burdock particle and pueraria lobata particle immerse in ethanol solution respectively, 1~3h of ultrasonic extraction, after extraction, warp
Filtering, concentration, dry, crushing obtain Notogineng Extract, Salvia root P.E, burdock extract, kudzu root extract.
5. the composition for the treatment of cardiovascular and cerebrovascular disease according to claim 1, it is characterised in that：The Folium Mori fermented product,
Feed with paper-mulberry leaf fermentate is to be made using following methods：
After mulberry leaf, feed with paper-mulberry leaf are crushed respectively, be separately added into 0.8~1.2 times of its quality dehydrated potato powder and 0.3~0.7 times
Water accesses the saccharomycete of its quality 2% after mixing, is placed in 28~30 DEG C of Anaerobic culturels 3~5 days, through 20~30 DEG C of vacuum
After drying, ultramicro grinding is carried out, Folium Mori fermented product, feed with paper-mulberry leaf fermentate are obtained.
6. the composition for the treatment of cardiovascular and cerebrovascular disease according to claim 1, it is characterised in that：The Pine Bark
It is to be made using following methods：
Pine bark is crushed to 200~800 mesh powders, under the conditions of 4~25 DEG C, the powder of gained is added to the water, ultrasound
1~3h is extracted, through filtering, concentrating obtained Pine Bark, wherein the water is 10~15 times of the weight of pine bark powder.
7. treating the composition of cardiovascular and cerebrovascular disease according to claim 1 any one of them, it is characterised in that：The bee pupa is more
Peptide is to be made using following methods：
Bee pupa is crushed to 100~300 mesh powders, under conditions of 20~40 DEG C, the powder of gained is added in petroleum ether
Degreasing, air-dry obtain the bee pupa powder of degreasing；The bee pupa powder of the degreasing of gained is mixed with protease under the conditions of 40~50 DEG C
3~4h is hydrolyzed after conjunction, then is warming up to 10~20min of standing at 95~100 DEG C, is centrifuged, is concentrated in vacuo and is freeze-dried
Obtain bee pupa polypeptide.
8. a kind of preparation method of the composition for the treatment of cardiovascular and cerebrovascular disease as described in any one of claim 1 to 7, feature
It is, includes the following steps：
By formula ratio, by grape seed extract, natto extract, Notogineng Extract, Salvia root P.E, burdock extract, sea-buckthorn
Extract, kudzu root extract, Pine Bark, bee pupa polypeptide, Folium Mori fermented product, feed with paper-mulberry leaf fermentate and arabinose powder are mixed
Close the composition that treatment cardiovascular and cerebrovascular disease is uniformly made.
9. a kind of composition for the treatment of cardiovascular and cerebrovascular disease as described in any one of claim 1 to 7 is in preparing health food
Application.
10. a kind of composition for the treatment of cardiovascular and cerebrovascular disease as described in any one of claim 1 to 7 is preparing treatment heart and brain blood
Application in the drug of pipe.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810590070.5A CN108498782A (en) | 2018-06-08 | 2018-06-08 | A kind of composition and preparation method thereof for treating cardiovascular and cerebrovascular disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810590070.5A CN108498782A (en) | 2018-06-08 | 2018-06-08 | A kind of composition and preparation method thereof for treating cardiovascular and cerebrovascular disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108498782A true CN108498782A (en) | 2018-09-07 |
Family
ID=63403113
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810590070.5A Withdrawn CN108498782A (en) | 2018-06-08 | 2018-06-08 | A kind of composition and preparation method thereof for treating cardiovascular and cerebrovascular disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108498782A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111418842A (en) * | 2020-03-31 | 2020-07-17 | 山西纳安健康科技有限公司 | Oral peony paste with heat clearing and detoxifying functions and preparation method thereof |
-
2018
- 2018-06-08 CN CN201810590070.5A patent/CN108498782A/en not_active Withdrawn
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111418842A (en) * | 2020-03-31 | 2020-07-17 | 山西纳安健康科技有限公司 | Oral peony paste with heat clearing and detoxifying functions and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101855821B1 (en) | Composition for relieving of menopausal symptoms and improving blood circulation | |
| JP2017514894A (en) | Method for producing garlic fermentation composition and garlic fermentation composition produced by the method | |
| Maud et al. | Ethno-pharmacological screening of Vernonia amygdalina and Cleome gynandra traditionally used in Childbirth in Western Uganda | |
| CN106344648A (en) | Thymus plant extract and application thereof | |
| CN101461843A (en) | Medicament composition for ischemic disease and application thereof in medicinal preparation | |
| CN105943613A (en) | Application of whole hemp extract in preparation of drug for preventing and controlling cardiovascular and cerebrovascular diseases | |
| CN107496573A (en) | Application of the houttuynia extract in the pharmaceutical preparation for preparing preventing and treating myocardial ischemia-reperfusion injury relevant disease | |
| CN108498782A (en) | A kind of composition and preparation method thereof for treating cardiovascular and cerebrovascular disease | |
| CN106389535A (en) | Application of industrial hemp cannaboid in preparing gout treating medicines | |
| CN103100028A (en) | Soft capsule favorable for reducing alcoholic liver injury and preparation method thereof | |
| CN107213455A (en) | A kind of stem cell medicine and its preparation method and application | |
| Hooper | A new medical dictionary: containing an explanation of the terms in anatomy, physiology... and the various branches of natural philosophy connected with medicine | |
| CN105727200A (en) | New application of salviae miltiorrhizae and pericarpium trichosanthis formula and medicine composition used for treating chronic pulmonary I type heart disease | |
| CN101411698A (en) | Use of salvia root salvianolic acid A | |
| CN105617271B (en) | A kind of health liquor and preparation method thereof for preventing and treating atherosclerosis | |
| CN105079495B (en) | A kind of alleviation physical fatigue and the health drink of reducing blood lipid and preparation method thereof | |
| CN1718191A (en) | Total secondary ginseng glucoside oral disintegration tablets prepn. method and application thereof | |
| CN107929372A (en) | Treat Chinese medicine composition of onychomycosis and its preparation method and application | |
| CN103690771B (en) | Be used for the treatment of medicine of lamb colibacillosis and preparation method thereof | |
| CN116920040B (en) | Traditional Chinese medicine composition for treating acute myocardial infarction and preparation and application thereof | |
| CN107397860A (en) | A kind of anti-tumor biological Chinese medicine preparation and processing technology | |
| CN109568481A (en) | A kind of Chinese prescription preparation for treating coronary heart disease | |
| CN105770474A (en) | Lupus erythematosus resisting drug for combined immunization and preparing method and application thereof | |
| CN104998078A (en) | Traditional Chinese medicine for treating infectious endocarditis | |
| CN103598622A (en) | Sea cucumber nutrient tablet and application method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20180907 |